A receptor profile describes the targets a drug binds to and what it does after binding. Second-generation antipsychotics commonly affect D2 and 5-HT2A receptors, with varying actions at histamine, muscarinic and adrenergic receptors. Some also partially activate particular dopamine or serotonin receptors.
Second-generation antipsychotics are a diverse group often called atypical antipsychotics. Most combine dopamine-related effects with substantial serotonin receptor actions, but there is no single receptor profile shared by every member. Their introduction expanded treatment options without eliminating the need to assess each medicine’s benefits, physical effects and subjective tolerability.
These differences help explain sedation, appetite changes, dizziness and other effects. However, a receptor chart is not a complete clinical prediction. Affinity depends on assay conditions, and actual engagement depends on exposure. Active metabolites may add relevant actions. Norquetiapine, for example, has properties that differ from its parent drug. Strong binding at one target does not establish an independent benefit in cognition or mood. Profiles are best used to generate informed expectations that are checked against trials and the person’s actual response, rather than as a substitute for clinical evidence.
A lower affinity value in an assay generally indicates stronger binding, but comparisons require compatible methods. It does not follow that the strongest-binding drug is the most effective clinically. Concentration at the target, duration of engagement and functional action all matter. Receptor tables are useful maps of possibilities whose relevance needs confirmation through treatment studies and individual review.
Further reading: DailyMed prescribing information (1); DailyMed prescribing information (2).
Comments are closed, but trackbacks and pingbacks are open.